On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Subscribe With Confidence

Stocks to Buy Now (STBN) is Here to Protect Your Privacy and Inbox.

Your privacy and inbox are safe. What does this mean? Stocks to Buy Now via AWeber responsibly manages email marketing campaigns as follows:

  • STBN will send you email if you give them permission to do so (by subscribing to their mailing list). We will respect your permission.
  • STBN will only send you email that is related to what you subscribed to and why you subscribed.
  • STBN will abide by AWeber’s anti-spam rules and anti-spam laws like CAN-SPAM.
  • You can unsubscribe whenever you want with a click of your mouse.

“What If I Want To Unsubscribe?”

At the end of every email you receive from this website you will see an unsubscribe link. Click on that link and you will see an unsubscribe page with two columns marked “Subscribed” and “Unsubscribed”. Click on the button in the “Unsubscribed” column. We will immediately unsubscribe you!

How Does Stocks to Buy Now Prevent Spam and Protect Inboxes?

  • Our email partner AWeber reviews customers’ mailing lists with a variety of automatic tests.
  • Our email partner AWeber manually reviews mailing lists for any signs of irresponsible emailing.

This two-pronged approach has helped keep spammers off AWeber ever since we started managing email in 1998.

To make sure we can keep them off, we share ideas with others in several email industry and anti-spam groups like the Messaging Anti-Abuse Working Group, the Anti-Phishing Working Group and the Online Trust Alliance.

 

 

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.